

ABSTRACT

The EB1-3-p35 cytokine is shown for the first time to be capable of inhibiting immune responses mediated or controlled by T cells via an effect on suppressor T cells. This suggests that EB13-p35 may be therapeutically effective in a variety of inflammatory and autoimmune conditions including arthritis, atherosclerosis, allograft rejection, and allergies such as asthma.